Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects - PubMed (original) (raw)
Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects
W Zhou et al. Bioorg Med Chem Lett. 1998.
Abstract
Mixed-backbone oligonucleotides containing alternative phosphorothioate and phosphodiester linkages in the 2'-O-methylribonucleosides segment show increased affinity with complementary targets, increased stability towards nucleases in vitro and in vivo, and reduced phosphorothioate-related prolongation of partial thromboplastin time compared to phosphorothioate oligodeoxynucleotides, thereby providing antisense agents with reduced side effects.
Similar articles
- Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS.
Peng Ho S, Livanov V, Zhang W, Li J, Lesher T. Peng Ho S, et al. Brain Res Mol Brain Res. 1998 Nov 12;62(1):1-11. doi: 10.1016/s0169-328x(98)00185-5. Brain Res Mol Brain Res. 1998. PMID: 9795101 - Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras.
Monia BP, Johnston JF, Sasmor H, Cummins LL. Monia BP, et al. J Biol Chem. 1996 Jun 14;271(24):14533-40. doi: 10.1074/jbc.271.24.14533. J Biol Chem. 1996. PMID: 8662854 - Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides.
Agrawal S. Agrawal S. Biochim Biophys Acta. 1999 Dec 10;1489(1):53-68. doi: 10.1016/s0167-4781(99)00141-4. Biochim Biophys Acta. 1999. PMID: 10806997 Review. - Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets.
Kawasaki AM, Casper MD, Freier SM, Lesnik EA, Zounes MC, Cummins LL, Gonzalez C, Cook PD. Kawasaki AM, et al. J Med Chem. 1993 Apr 2;36(7):831-41. doi: 10.1021/jm00059a007. J Med Chem. 1993. PMID: 8464037 - Pharmacokinetics of oligonucleotides.
Agrawal S, Zhang R. Agrawal S, et al. Ciba Found Symp. 1997;209:60-75; discussion 75-8. doi: 10.1002/9780470515396.ch6. Ciba Found Symp. 1997. PMID: 9383569 Review.
Cited by
- Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic.
Rook ME, Southwell AL. Rook ME, et al. BioDrugs. 2022 Mar;36(2):105-119. doi: 10.1007/s40259-022-00519-9. Epub 2022 Mar 7. BioDrugs. 2022. PMID: 35254632 Free PMC article. Review. - Introduction and History of the Chemistry of Nucleic Acids Therapeutics.
Gait MJ, Agrawal S. Gait MJ, et al. Methods Mol Biol. 2022;2434:3-31. doi: 10.1007/978-1-0716-2010-6_1. Methods Mol Biol. 2022. PMID: 35213007 Free PMC article. - The Evolution of Antisense Oligonucleotide Chemistry-A Personal Journey.
Agrawal S. Agrawal S. Biomedicines. 2021 May 3;9(5):503. doi: 10.3390/biomedicines9050503. Biomedicines. 2021. PMID: 34063675 Free PMC article. Review. - MicroRNA-feedback loop as a key modulator of liver tumorigenesis and inflammation.
Gougelet A, Colnot S. Gougelet A, et al. World J Gastroenterol. 2013 Jan 28;19(4):440-4. doi: 10.3748/wjg.v19.i4.440. World J Gastroenterol. 2013. PMID: 23382622 Free PMC article. - Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.
Mansoor M, Melendez AJ. Mansoor M, et al. Gene Regul Syst Bio. 2008 Sep 22;2:275-95. doi: 10.4137/grsb.s418. Gene Regul Syst Bio. 2008. PMID: 19787090 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources